Successful management of a lung cancer patient harbouring both mutation and fusion gene with disseminated intravascular coagulation.

Lung cancer patients harbouring driver oncogene alterations are markedly responsive to molecular target agents, such as (), tyrosine kinase inhibitor (TKI), and ()-TKI. We encountered an exceptionally rare case, harbouring both mutation and fusion gene, and suffering from severe disseminated intravascular coagulation. In this case report, we present two notable points. First, our patient was successfully treated with a third-generation -TKI, osimertinib. Second, osimertinib could manage severe conditions, such as disseminated intravascular coagulation. Third-generation -TKIs may be a viable option for patients harbouring both mutations and fusion genes, even in severe conditions.